Coverart for item
The Resource Evaluating clinical research : all that glitters is not gold, Bengt D. Furbert and Curt D. Furberg

Evaluating clinical research : all that glitters is not gold, Bengt D. Furbert and Curt D. Furberg

Label
Evaluating clinical research : all that glitters is not gold
Title
Evaluating clinical research
Title remainder
all that glitters is not gold
Statement of responsibility
Bengt D. Furbert and Curt D. Furberg
Creator
Contributor
Subject
Language
eng
Cataloging source
BTCTA
http://library.link/vocab/creatorName
Furberg, Bengt
Illustrations
illustrations
Index
index present
LC call number
R853.C55
LC item number
F87 2007
Literary form
non fiction
Nature of contents
bibliography
http://library.link/vocab/relatedWorkOrContributorName
  • Furberg, Curt
  • Furberg, Bengt
http://library.link/vocab/subjectName
  • Clinical medicine
  • Clinical trials
  • Medicine
  • Clinical Trials as Topic
  • Research Design
Label
Evaluating clinical research : all that glitters is not gold, Bengt D. Furbert and Curt D. Furberg
Instantiates
Publication
Note
Rev. ed. of: All that glitters is not gold : what clinicians need to know about clincial trials / Bengt Furberg and Curt Furberg. Dr. Potata, c1994
Bibliography note
Includes bibliographical references (pages 149-158) and index
Carrier category
volume
Carrier category code
nc
Carrier MARC source
rdacarrier
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
What is the purpose of this book? -- Why is benefit-to-harm balance essential to treatment decisions? -- What are the strengths of randomized controlled clinical trials? -- What are the weaknesses of randomized controlled clinical trials? -- Do meta-analyses provide the ultimate truth? -- What are the strengths of observational studies? -- What are the weaknesses of observational studies? -- Were the scientific questions stated in advance? -- Were the treatment groups comparable initially? -- Why is blinding/masking so important? -- How is symptomatic improvement measured? -- Is it really possible to assess quality of life -- What is the value of biologic markers in drug evaluation? -- How are adverse drug reactions measured? -- How representative are study subjects in clinical trials? -- What happened to the study subjects who disappeared from the analysis? -- How reliable are active-control trials? -- How informative are composite outcomes? -- Do changes in biologic markers predict clinical benefit? -- How trustworthy are the authors? -- Does publication in a reputable scientific journal guarantee quality? -- Is it necessary to be a biostatistician to interpret scientific data? -- Are all drugs of a class interchangeable? -- How much confidence can be placed on economic analysis? -- How should I handle the massive flow of information? -- How well is research translated into clinical care?
Control code
154711997
Dimensions
24 cm
Edition
2nd ed.
Extent
161 pages
Isbn
9780387728988
Lccn
2007930204
Media category
unmediated
Media MARC source
rdamedia
Media type code
n
Other physical details
illustrations
System control number
(OCoLC)154711997
Label
Evaluating clinical research : all that glitters is not gold, Bengt D. Furbert and Curt D. Furberg
Publication
Note
Rev. ed. of: All that glitters is not gold : what clinicians need to know about clincial trials / Bengt Furberg and Curt Furberg. Dr. Potata, c1994
Bibliography note
Includes bibliographical references (pages 149-158) and index
Carrier category
volume
Carrier category code
nc
Carrier MARC source
rdacarrier
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
What is the purpose of this book? -- Why is benefit-to-harm balance essential to treatment decisions? -- What are the strengths of randomized controlled clinical trials? -- What are the weaknesses of randomized controlled clinical trials? -- Do meta-analyses provide the ultimate truth? -- What are the strengths of observational studies? -- What are the weaknesses of observational studies? -- Were the scientific questions stated in advance? -- Were the treatment groups comparable initially? -- Why is blinding/masking so important? -- How is symptomatic improvement measured? -- Is it really possible to assess quality of life -- What is the value of biologic markers in drug evaluation? -- How are adverse drug reactions measured? -- How representative are study subjects in clinical trials? -- What happened to the study subjects who disappeared from the analysis? -- How reliable are active-control trials? -- How informative are composite outcomes? -- Do changes in biologic markers predict clinical benefit? -- How trustworthy are the authors? -- Does publication in a reputable scientific journal guarantee quality? -- Is it necessary to be a biostatistician to interpret scientific data? -- Are all drugs of a class interchangeable? -- How much confidence can be placed on economic analysis? -- How should I handle the massive flow of information? -- How well is research translated into clinical care?
Control code
154711997
Dimensions
24 cm
Edition
2nd ed.
Extent
161 pages
Isbn
9780387728988
Lccn
2007930204
Media category
unmediated
Media MARC source
rdamedia
Media type code
n
Other physical details
illustrations
System control number
(OCoLC)154711997

Library Locations

    • J. Otto Lottes Health Sciences LibraryBorrow it
      1 Hospital Dr, Columbia, MO, 65201, US
      38.939544 -92.328377
Processing Feedback ...